Patent classifications
C07D235/28
INHIBITORS OF NHR2 AND/OR RUNX1/ETO-TETRAMERIZATION
The invention relates to inhibitors of the NHR2 tetramerization and their use as tumor therapeutics (e.g. against acute myeloid leukemia (AML)), cytostatics, and diagnostic agents.
INHIBITORS OF NHR2 AND/OR RUNX1/ETO-TETRAMERIZATION
The invention relates to inhibitors of the NHR2 tetramerization and their use as tumor therapeutics (e.g. against acute myeloid leukemia (AML)), cytostatics, and diagnostic agents.
Diarylsulfide backbone containing photolabile protecting groups
The present disclosure relates to photoactivable protecting groups containing a diarylsulfide chromophore, a method for the synthesis thereof and their use as photoactivable protecting groups using maskless photolithography based array synthesis. ##STR00001##
Diarylsulfide backbone containing photolabile protecting groups
The present disclosure relates to photoactivable protecting groups containing a diarylsulfide chromophore, a method for the synthesis thereof and their use as photoactivable protecting groups using maskless photolithography based array synthesis. ##STR00001##
Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
- Robert J. Altenbach ,
- Andrew Bogdan ,
- Sylvain Couty ,
- Nicolas Desroy ,
- Gregory A. Gfesser ,
- Christopher Gaëtan Housseman ,
- Philip R. Kym ,
- Bo Liu ,
- Thi Thu Trang Mai ,
- Karine Fabienne Malagu ,
- Nuria Merayo Merayo ,
- Olivier Laurent Picolet ,
- Mathieu Rafaël Pizzonero ,
- Xenia B. Searle ,
- Steven Emiel Van der Plas ,
- Xueqing Wang ,
- Ming C. Yeung
The invention discloses compounds of Formula (I), ##STR00001##
wherein A.sup.1, R.sup.1, R.sup.2, R.sup.3, R.sup.4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
- Robert J. Altenbach ,
- Andrew Bogdan ,
- Sylvain Couty ,
- Nicolas Desroy ,
- Gregory A. Gfesser ,
- Christopher Gaëtan Housseman ,
- Philip R. Kym ,
- Bo Liu ,
- Thi Thu Trang Mai ,
- Karine Fabienne Malagu ,
- Nuria Merayo Merayo ,
- Olivier Laurent Picolet ,
- Mathieu Rafaël Pizzonero ,
- Xenia B. Searle ,
- Steven Emiel Van der Plas ,
- Xueqing Wang ,
- Ming C. Yeung
The invention discloses compounds of Formula (I), ##STR00001##
wherein A.sup.1, R.sup.1, R.sup.2, R.sup.3, R.sup.4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
- Robert J. Altenbach ,
- Andrew Bogdan ,
- Sylvain Couty ,
- Nicolas Desroy ,
- Gregory A. Gfesser ,
- Christopher Gaëtan Housseman ,
- Philip R. Kym ,
- Bo Liu ,
- Thi Thu Trang Mai ,
- Karine Fabienne Malagu ,
- Nuria Merayo Merayo ,
- Olivier Laurent Picolet ,
- Mathieu Rafaël Pizzonero ,
- Xenia B. Searle ,
- Steven Emiel Van der Plas ,
- Xueqing Wang ,
- Ming C. Yeung
The invention discloses compounds of Formula (I), ##STR00001##
wherein A.sup.1, R.sup.1, R.sup.2, R.sup.3, R.sup.4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
- Robert J. Altenbach ,
- Andrew Bogdan ,
- Sylvain Couty ,
- Nicolas Desroy ,
- Gregory A. Gfesser ,
- Christopher Gaëtan Housseman ,
- Philip R. Kym ,
- Bo Liu ,
- Thi Thu Trang Mai ,
- Karine Fabienne Malagu ,
- Nuria Merayo Merayo ,
- Olivier Laurent Picolet ,
- Mathieu Rafaël Pizzonero ,
- Xenia B. Searle ,
- Steven Emiel Van der Plas ,
- Xueqing Wang ,
- Ming C. Yeung
The invention discloses compounds of Formula (I), ##STR00001##
wherein A.sup.1, R.sup.1, R.sup.2, R.sup.3, R.sup.4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
METHOD FOR MONITORING FLUORESCENT POLYMER ANTISCALANTS IN INDUSTRIAL WATER SYSTEMS
The present invention relates to a fluorescently-tagged (co)polymer and use thereof useful as a scale inhibitor in industrial water systems. Said (co)polymer comprises a (i) reactive fluorescent compound selected from a benzodiazole compound (ii) at least one monoethylenically unsaturated acid monomer, and (iii) optionally, at least one monoethylenically unsaturated acid-free monomer.
Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
- Robert J. Altenbach ,
- Andrew Bogdan ,
- Sylvain Couty ,
- Nicolas Desroy ,
- Gregory A. Gfesser ,
- Christopher Gaëtan Housseman ,
- Philip R. Kym ,
- Bo Liu ,
- Thi Thu Trang Mai ,
- Karine Fabienne Malagu ,
- Nuria Merayo Merayo ,
- Olivier Laurent Picolet ,
- Mathieu Rafaël Pizzonero ,
- Xenia B. Searle ,
- Steven Emiel Van der Plas ,
- Xueqing Wang ,
- Ming C. Yeung
The invention discloses compounds of Formula (I), ##STR00001##
wherein A.sup.1, R.sup.1, R.sup.2, R.sup.3, R.sup.4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.